Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Exp Neurol ; 275 Pt 1: 104-15, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26363496

ABSTRACT

Mutation of leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of both familial and sporadic Parkinson's disease (PD) cases. Several mutations in LRRK2 gene were reported in PD patients. R1441 is the second most frequent site of LRRK2 mutation. We generated (R1441C) LRRK2 transgenic mice that displayed motor deficits at the age of 16 months. Compared with wild-type mice, 16-month-old (R1441C) LRRK2 mice exhibited a significant reduction in the number of substantia nigra (SN) dopaminergic neurons. To elucidate molecular pathogenic pathways involved in (R1441C) LRRK2-induced death of SN dopaminergic neurons, we performed microarray analysis to visualize altered mRNA expressions in the SN of (R1441C) LRRK2 mouse. In the SN of (R1441C) LRRK2 transgenic mouse, the mRNA expression of three genes that promote cell death was upregulated, while the mRNA expression of seven genes that contribute to neurogenesis/neuroprotection was significantly downregulated. Our results suggest that altered expression of these genes involved in regulating neuronal survival may contribute to the pathogenesis of (R1441C) LRRK2-induced PD.


Subject(s)
Cell Survival/genetics , Dopaminergic Neurons/metabolism , Gene Expression Regulation , Nerve Degeneration/metabolism , Protein Serine-Threonine Kinases/metabolism , Substantia Nigra/metabolism , Animals , Dopaminergic Neurons/pathology , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Levodopa/pharmacology , Mice , Mice, Transgenic , Motor Activity/drug effects , Motor Activity/genetics , Nerve Degeneration/genetics , Nerve Degeneration/pathology , Neurogenesis/genetics , Protein Serine-Threonine Kinases/genetics , Substantia Nigra/pathology
2.
Neurobiol Dis ; 68: 190-9, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24830390

ABSTRACT

Twelve- to sixteen-month-old (G2019S) LRRK2 transgenic mice prepared by us displayed progressive neuronal death of substantia nigra pars compacta (SNpc) dopaminergic cells. In the present study, we hypothesized that prior to a late-phase death of SNpc dopaminergic neurons, (G2019S) LRRK2 also causes an early-phase neuronal dysfunction of SNpc dopaminergic cells in the (G2019S) LRRK2 mouse. Eight to nine-month-old (G2019S) LRRK2 transgenic mice exhibited the symptom of hypoactivity in the absence of the degeneration of SNpc dopaminergic neurons or nigrostriatal dopaminergic terminals. Whole-cell current-clamp recordings of SNpc dopaminergic cells in brain slices demonstrated a significant decrease in spontaneous firing frequency of SNpc dopaminergic neurons of 8-month-old (G2019S) LRRK2 mice. Carbon fiber electrode amperometry recording using striatal slices showed that (G2019S) LRRK2 transgenic mice at the age of 8 to 9months display an impaired evoked dopamine release in the dorsolateral striatum. Normal nigrostriatal dopaminergic transmission is required for the induction of long-term synaptic plasticity expressed at corticostriatal glutamatergic synapses of striatal medium spiny neurons. Whole-cell voltage-clamp recordings showed that in contrast to medium spiny neurons of 8 to 9-month-old wild-type mice, high-frequency stimulation of corticostriatal afferents failed to induce long-term depression (LTD) of corticostriatal EPSCs in medium spiny neurons of (G2019S) LRRK2 mice at the same age. Our study provides the evidence that mutant (G2019S) LRRK2 causes early-phase dysfunctions of SNpc dopaminergic neurons, including a decrease in spontaneous firing rate and a reduction in evoked dopamine release, and impairment of corticostriatal LTD in the (G2019S) LRRK2 transgenic mouse.


Subject(s)
Dopaminergic Neurons/physiology , Long-Term Potentiation/genetics , Mutation/genetics , Parkinson Disease , Protein Serine-Threonine Kinases/genetics , Substantia Nigra/pathology , Animals , Apomorphine/pharmacology , Cerebral Cortex/physiopathology , Corpus Striatum/physiopathology , Dopamine Agonists/pharmacology , GABA Antagonists/pharmacology , Glycine/genetics , Humans , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Long-Term Potentiation/drug effects , Mice , Mice, Transgenic , Motor Activity/genetics , Parkinson Disease/genetics , Parkinson Disease/pathology , Parkinson Disease/physiopathology , Picrotoxin/pharmacology , Radionuclide Imaging , Serine/genetics , Substantia Nigra/diagnostic imaging , Tyrosine 3-Monooxygenase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...